🔓 Unlock the full profile of Josh Disbrow (Aytu Biopharma), including verified contact details, financial insights, and professional associations.
See Josh Disbrow Full ProfileBelow are the ✅ Verified Contact Details to help you connect directly:
Email: jos*****@ayt******.com
Mobile: 94488*****
Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)
Key Insights You Should Know About This Individual
- Josh Disbrow is a Co-Founder and Chief Executive Officer of Aytu BioPharma, an organization founded in April 2015, focusing on innovative therapeutics in the healthcare sector.
- Under Disbrow's leadership, Aytu BioPharma has been publicly traded on NASDAQ under the symbol AYTU, enhancing the company's visibility and allowing for capital growth.
- Aytu BioPharma, led by Disbrow, has focused on commercializing prescription products and bringing unique treatment options to market, positively impacting patient care.
- In addition to leading Aytu BioPharma, Disbrow serves on the Board of Directors and chairs the Nominating and Governance Committee for Zynex Medical since March 2018, further showcasing leadership capabilities in the healthcare field.
- Disbrow will join the University of Colorado Colorado Springs in December 2024 as a Strategic Artificial Intelligence Advisory Member, indicating a commitment to integrating advanced technology in therapeutic development.
- Prior to Aytu BioPharma, Disbrow held various leadership roles, including Chief Operating Officer at Ampio Pharmaceuticals and Vice President of Commercial Operations at Arbor Pharmaceuticals, showcasing an extensive background in biopharmaceutical management.
- Throughout the career, Disbrow has navigated various challenges in the pharmaceutical industry, from product development to regulatory hurdles, demonstrating resilience and adaptability.
- The market cap of Aytu BioPharma is noted to be $7.5 million, reflecting the ongoing challenges and growth opportunities within the competitive pharmaceutical landscape.